Tagged Articles

cirrhosis 3 articles

Exposure to thirdhand smoke an ‘under-appreciated health risk’

The ill effects of cigarettes have been shown to affect not only smokers but also those exposed to the smoke second hand. New research shows that thirdhand smoke – the invisible remnants of tobacco smoke that clings to surfaces and dust particles – could also be putting several billion people at an “under-appreciated health risk.” Even the most courteous of smokers can be leaving behind tobacco residue that can be dangerous, say researchers from the University of California-Riverside. They reference previous studies that show children living with adults who smoke are absent from school 40 percent more days than children ... Read More

Study on hepatitis C drug halted after patient suffers heart failure

Bristol-Myers Squibb Co. pulling the plug on a study for a drug to treat hepatitis C after a patient suffered heart failure. The drug BMS-986094, formerly known as INX-189, was in Phase II trials. The drug is a nucleotide polymerase inhibitor, or “nuke.” The drug was being tested as a treatment for hepatitis C, a viral disease that leads to inflammation of the liver. Chronic infections can lead to scarring of the liver and ultimately to cirrhosis. In some cases, those with cirrhosis will go on to develop liver failure, liver cancer, or life-threatening esophageal and gastric varices. The disease ... Read More

FDA warns of link between cholesterol drug, muscle injury

More bad news for the cholesterol-lowering drug Vytorin. The drug has been under scrutiny lately for everything from elevated cancer risk and serious side effects to ineffectiveness. This week, the Food and Drug Administration (FDA) issued a safety announcement about simvastatin, one of the two active ingredients found in the medication, and an increased risk of a potentially life-threatening muscle injury. Vytorin combines simvastatin (sold as in individual ingredient under the brand name Zocor) and ezetimibe (also known as Zetia) to reduce the production of “bad” cholesterol. An FDA review of data from clinical studies, adverse event reports, and prescription ... Read More